← All organizations
Santen Inc.
Also known as: SANTEN | Santen Gmbh | Santen Inc. | Santen Oy | Santen Pharmaceutical | Santen Pharmaceutical Asia Pte. Ltd. | Santen Pharmaceutical(China) Co.,LTD | Santen Pharmaceutical Co., Ltd. | Santen Pharmaceutical (Taiwan) Co., LTD | Santen SAS
Highest phase reached
Phase 4
First clinical trial
Sep 1, 2003First marketed drug
Sep 24, 1999First NDA
Sep 24, 1999Last known activity
Mar 17, 2025
Timeline
1890s
- Jun 1, 1890
Santen Inc.— Founded
1990s
- Sep 24, 1999
pemirolast— NDA Organization
2000s
- Aug 18, 2000
levofloxacin— NDA Secondary Org
- Aug 18, 2000
sodium chloride— Marketing Organization
2010s
- Sep 28, 2011
Novagali— Acquired
2020s
- Dec 19, 2021
Eyevance— Acquired
Drugs by trial phase (39 distinct, 92 trials)
Phase 4 (6 own, 0 via acquisition)
Phase 3 (12 own, 0 via acquisition)
Phase 2 (17 own, 1 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Asthma
- Atrophy
- Cataract
- Choroidal Neovascularization
- Conjunctivitis
- Conjunctivitis, Allergic
- Diabetic Retinopathy
- Dry Eye Syndromes
- Edema
- Endophthalmitis
- Eye Diseases
- Eye Injuries, Penetrating
- Geographic Atrophy
- Glaucoma
- Glaucoma, Open-Angle
- Hypertension
- Keratitis
- Keratoconjunctivitis
- Keratoconjunctivitis Sicca
- Macular Degeneration
- Macular Edema
- Myopia
- Neovascularization, Pathologic
- Ocular Hypertension
- Panuveitis
- Pars Planitis
- Retinal Diseases
- Retinal Vein Occlusion
- Signs and Symptoms
- Syndrome
- Uveitis
- Uveitis, Intermediate
- Uveitis, Posterior
Marketed drugs (5)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT06911216Lead sponsorEarly Phase 1Mar 17, 2025
- NCT06666855Lead sponsorPhase 3Nov 30, 2024
- NCT06514612Lead sponsorPhase 3Nov 1, 2024
- NCT06683651Lead sponsorPhase 3Oct 22, 2024
- NCT05905653Lead sponsorPhase 1May 25, 2023
- NCT05193331CollaboratorN/AApr 1, 2023
- NCT05665387Lead sponsorPhase 2Dec 19, 2022
- NCT06146881CollaboratorPhase 2Oct 2, 2022
- NCT05495061Lead sponsorPhase 3Aug 9, 2022
- NCT05503901Lead sponsorPhase 3Aug 8, 2022
- NCT05376176Lead sponsorPhase 2May 19, 2022
- NCT04742283Lead sponsorPhase 2Dec 17, 2020
- NCT04492878CollaboratorPhase 4Feb 4, 2020
- NCT04214821CollaboratorPhase 1/Phase 2Sep 23, 2019
- NCT04212429CollaboratorPhase 1/Phase 2Sep 23, 2019
Details
- Founded
- Osaka, JP Jun 1, 1890
- First NDA
- Sep 24, 1999
- Last known activity
- Mar 17, 2025
Designations held
- Priority review